Solizmestrocel for bronchopulmonary dysplasia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 10 Jul 2025: Trial registered, NCT07058025

The trials

NCT07058025: Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants

State
Not started
Phase
Phase 2
People
168 planned
Started
1 Oct 2025
Primary completion
30 Sep 2028
Arms
Intervention group will receive multiple IV doses of UC-MSCs
Results
None posted
  1. 10 Jul 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Also known as Human Allogenic Umbilical Cord Mesenchymal Stromal Cells, Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100 million UC-MSC., Uc-msc, Umbilical Cord-Derived Mesenchymal Stem Cells, XytriX.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.